NCT05562024View on ClinicalTrials.gov

TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 30, 2022

Primary Completion Date

December 18, 2025

Study Completion Date

February 18, 2039

Conditions
B7-H3-positive Relapsed/ Refractory Neuroblastoma
Interventions
BIOLOGICAL

T cell injection targeting B7-H3 chimeric antigen receptor

The subjects will be administered once.

Trial Locations (2)

250000

NOT_YET_RECRUITING

Shandong Cancer Hospital and Institute, Jinan

300000

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

Sponsors
All Listed Sponsors
collaborator

Tianjin Medical University Cancer Institute and Hospital

OTHER

collaborator

Shandong Cancer Hospital and Institute

OTHER

lead

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

INDUSTRY